Agilent Technologies Array CGH Platform Assures Quality of Cancer Cell Lines Used in Biomedical Research

摘要

SANTA CLARA, Calif. - Agilent Technologies Inc. announced on July 28 that scientists using the company's comparative genomic hybridisation (CGH) technology have shown that cancer cell lines, which are broadly used in all aspects of biomedical research, may have vast differences in their genetic makeup, even when grown in the same batch.